Nephrology

Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1

Presented By

Dr Wesley Hayes, Great Ormond Street Hospital for Children NHS, UK

Trial

Phase 3, ILLUMINATE-B

Conference

ERA 2025

Type

News article

11 June 2025 10:05

Ravulizumab improves long-term quality-of-life in atypical haemolytic uraemic syndrome

Trial

Phase 3

Conference

ERA 2025

Type

News article

11 June 2025 10:03

Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease

Presented By

Dr Georgios Koukos, Calico Life Sciences, CA, USA

Conference

ERA 2025

Type

News article

11 June 2025 10:01

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Presented By

Prof. Jonathan Barratt, University of Leicester, UK

Trial

Phase 3, NefIgArd

Conference

ERA 2025

Type

News article

11 June 2025 09:59

Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy

Trial

Phase 3, APPEAR-C3G

Conference

ERA 2025

Type

News article

11 June 2025 09:57

Sibeprenlimab is an emerging treatment option for IgA nephropathy

Presented By

Prof. Vlado Perkovic, University of New South Wales, Australia

Trial

Phase 3, VISIONARY

Conference

ERA 2025

Type

News article

10 June 2025 10:41

Pegcetacoplan is treatment option for adolescents with C3G or IC-MPGN

Presented By

Dr Antonio Mastrangelo, Policlinico of Milan, Italy

Trial

Phase 3, VALIANT

Conference

ERA 2025

Type

News article

10 June 2025 10:39

Mineral receptor antagonists not beneficial for patients undergoing dialysis

Presented By

Dr Lonnie Pyne, McMaster University, Canada

Conference

ERA 2025

Type

News article

10 June 2025 10:38

Spironolactone not useful in dialysis with cardiovascular risk

Presented By

Dr Michael Walsh, McMaster University, Canada

Trial

Phase 3, ACHIEVE

Conference

ERA 2025

Type

News article

10 June 2025 10:36

Acute eGFR dip following empagliflozin initiation not associated with acute kidney injury

Presented By

Dr Natalie Staplin, University of Oxford, UK

Conference

ERA 2025

Type

News article

10 June 2025 10:34

Survival benefit from kidney transplantation depends on the donor source

Presented By

Prof. Rachel Hellemans, Antwerp University Hospital, Belgium

Conference

ERA 2025

Type

News article

6 June 2025 10:49

Canagliflozin has dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes

Presented By

Dr Elias Elenjickal, McGill University Health Centre, Canada

Trial

CANVAS

Conference

ERA 2025

Type

News article

6 June 2025 10:46

Large meta-analysis shows empagliflozin slows kidney progression and reduces risk among patients with multiple diseases

Presented By

Prof. William Herrington, University of Oxford, UK

Conference

ERA 2025

Type

News article

6 June 2025 10:43

Factor XI inhibition not useful for end-stage kidney disease patients receiving haemodialysis

Presented By

Prof. Wolfgang Winkelmayer, Baylor College of Medicine, TX, USA

Trial

Phase 2

Conference

ERA 2025

Type

News article

6 June 2025 10:41

Finerenone plus empagliflozin as new potential combination in patients with type 2 diabetes and chronic kidney disease

Presented By

Prof. Johannes Mann, Friedrich Alexander University, Germany

Trial

Phase 2, CONFIDENCE

Conference

ERA 2025

Type

News article

6 June 2025 10:40

Preview of the new KDIGO Guidelines for ADPKD, available later in 2024

Presented By

Dr Vicente Torres, Mayo Clinic, Rochester, MN, USA

Conference

ERA 2024

Type

News article

20 June 2024 19:49

APPEAR-C3G: Iptacopan shows promise for complement 3 glomerulopathy

Presented By

Prof. David Kavanagh, Newcastle University, United Kingdom

Trial

Phase 3, APPEAR-C3G

Conference

ERA 2024

Type

News article

20 June 2024 19:45

Anti-nephrin autoantibody positivity describes a unique subclass of podocytopathies

Presented By

Prof. Tobias B. Huber, University Medical Center Hamburg-Eppendorf, Germany

Conference

ERA 2024

Type

News article

20 June 2024 19:41

Active vitamin D plus low-dose prednisolone is an alternative to high-dose prednisolone in minimal change disease

Presented By

Dr Tilde Kristensen, Regional Hospital Viborg, Denmark

Trial

ADAPTinMCN

Conference

ERA 2024

Type

News article

20 June 2024 19:35

Claudin-1 is a potential antibody target for crescent glomerulonephritis

Presented By

Dr Jean-Daniel Delbet, Paris Centre de Recherche Cardiovasculaire, Paris, France

Trial

Phase 2, RENAL-F02

Conference

ERA 2024

Type

News article

20 June 2024 19:32

Rituximab protocol based on PLA2R1 epitope spreading outperforms the standard GEMRITUX protocol in membranous nephropathy

Presented By

Prof. Barbara Seitz-Polski, Université Côte d'Azur, Nice, France

Conference

ERA 2024

Type

News article

20 June 2024 19:26

The REACT score predicts relapse in ANCA-associated vasculitis

Presented By

Dr Gianmarco Lugli, Meyer Children's Hospital IRCCS, Florence, Italy

Conference

ERA 2024

Type

News article

20 June 2024 19:22

Semaglutide improves renal outcomes in overweight/obese participants with cardiovascular disease and no diabetes

Presented By

Prof. Helen M. Colhoun, The University of Edinburgh, United Kingdom

Trial

Phase 3, SELECT

Conference

ERA 2024

Type

News article

20 June 2024 19:19

Discrepancy between cardiovascular RCT participants and real-life CKD patients could limit generalisability of RCT results

Presented By

Julia M.T. Colombijn, University Medical Centre Utrecht, the Netherlands

Conference

ERA 2024

Type

News article

20 June 2024 19:16

MERCURI-1: Perioperative empagliflozin shows renal protection following cardiac surgery

Presented By

Dr Lars Snel, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 4, MERCURI-1

Conference

ERA 2024

Type

News article

20 June 2024 19:13

Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes

Presented By

Dr Uffe Heide-Jørgensen, Aarhus University, Aarhus, Denmark

Conference

ERA 2024

Type

News article

20 June 2024 19:09

Atrasentan shows positive interim results in IgA nephropathy: ALIGN phase 3 trial

Presented By

Prof. Hiddo J.L. Heerspink, University Medical Center Groningen, The Netherlands

Trial

Phase 3, ALIGN

Conference

ERA 2024

Type

News article

20 June 2024 19:05

Zigakibart slows down eGFR decline in IgA nephropathy

Presented By

Prof. Jonathan Barrat, University of Leicester, United Kingdom

Trial

Phase 1/2, ADU-CL-19

Conference

ERA 2024

Type

News article

20 June 2024 19:01

Long-term atacicept shows continued benefit in IgA nephropathy

Presented By

Prof. Richard Lafayette, Stanford University, CA, USA

Trial

Phase 2, ORIGIN

Conference

ERA 2024

Type

News article

20 June 2024 18:58

APPLAUSE-IgAN: Iptacopan improves proteinuria in IgA nephropathy

Presented By

Prof. Vlado Perkovic, University of New South Wales, Sydney, Australia

Trial

Phase 3, APPLAUSE-IgAN

Conference

ERA 2024

Type

News article

20 June 2024 18:53

CD38 inhibition by felzartamab promising for resolution of antibody-mediated rejection following kidney allografts

Presented By

Dr Katharina A. Mayer, Medical University of Vienna, Austria

Conference

ERA 2024

Type

News article

20 June 2024 18:36

Clazakizumab improves albumin and inflammation in participants undergoing haemodialysis

Trial

Phase 2, POSIBIL6ESKD

Conference

ERA 2024

Type

News article

20 June 2024 18:33

TATH trial: Twice-weekly haemodialysis can be an alternative to thrice weekly regimen

Presented By

Dr Mabel Aoun, Saint Joseph University of Beirut, Lebanon

Trial

TATH

Conference

ERA 2024

Type

News article

20 June 2024 18:30

KIR-HLA class I mismatch could be involved in antibody-mediated rejection of transplanted kidneys

Presented By

Ms Judith Federico-Vega, Hospital del Mar Research Institute, Barcelona, Spain

Conference

ERA 2024

Type

News article

20 June 2024 18:26

FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease

Presented By

Prof. Vlado Perkovic, University of New South Wales, Sydney, Australia

Trial

Phase 3, FLOW

Conference

ERA 2024

Type

News article

20 June 2024 18:19

Early phase data show albuminuria improvement with avenciguat

Presented By

Prof. Hiddo J.L. Heerspink, University Medical Center Groningen, The Netherlands

Conference

ERA 2024

Type

News article

20 June 2024 18:17

Rilparencel leads to kidney function stabilisation in chronic kidney disease and type 2 diabetes

Presented By

Dr Joseph Stavas, ProKidney LLC, Winston-Salem, NC, USA

Trial

Phase 2, REACT

Conference

ERA 2024

Type

News article

20 June 2024 18:13

The majority of real-world patients with CKD are not eligible for SGLT2 inhibitor trials

Presented By

Dr Anna Forbes, University of Oxford, United Kingdom

Conference

ERA 2024

Type

News article

20 June 2024 18:09

Meet the Experts: Navigating Kidneys and Genes

Expert

Prof. John Sayer (Newcastle University, UK) and Prof. Roman-Ulrich Müller (University Clinic Cologne, Germany)

Conference

ERA 2024

5 June 2024 10:01

ERA 2024 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ERA 2024

3 June 2024 14:25

Roxadustat shows increases in Hb regardless of prior roxadustat use in CKD

Trial

Phase 4

Conference

ASN 2023

Type

News article

28 November 2023 15:24

Aldosterone synthase inhibition reduces albuminuria in CKD

Presented By

Prof. Katherine Tuttle, University of Washington, WA, USA

Trial

Phase 2

Conference

ASN 2023

Type

News article

28 November 2023 15:23

Low doses of zibotentan with dapagliflozin improve albuminuria in patients with CKD

Presented By

Prof. Hiddo Heerspink, UMC Groningen, the Netherlands

Trial

Phase 2, ZENITH-CKD

Conference

ASN 2023

Type

News article

28 November 2023 15:20

Spironolactone failed to reduce major adverse cardiac effects in patients with CKD on haemodialysis

Presented By

Prof. Patrick Rossignol, University Hospital of Nancy, France

Trial

Phase 3, ALCHEMIST

Conference

ASN 2023

Type

News article

28 November 2023 15:18

Efficacy of bardoxolone methyl for DKD, without increased cardiac risk

Presented By

Dr Tadao Akizawa, Showa University School of Medicine, Japan

Trial

Phase 3, AYAME

Conference

ASN 2023

Type

News article

28 November 2023 15:12

New approaches to successful vascular access

Presented By

Dr Vandana Niyyar, Emory University, GA, USA

Conference

ASN 2023

Type

News article

28 November 2023 14:57

Patient care technicians improve haemodialysis patient outcomes

Presented By

Dr Laura Plantinga, Emory University, GA, USA

Conference

ASN 2023

Type

News article

28 November 2023 14:54

Haemodiafiltration increases longevity compared with haemodialysis, but does it improve patient satisfaction?

Trial

CONVINCE

Conference

ASN 2023

Type

News article

28 November 2023 14:51

Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery

Presented By

Prof. Daniel Brennan, Johns Hopkins Medicine, MD, USA

Trial

Phase 3, MDR-101-MLK

Conference

ASN 2023

Type

News article

28 November 2023 14:49

A systems approach to kidney transplantation disappoints

Presented By

Dr Amit Garg, McMaster University, Canada

Conference

ASN 2023

Type

News article

28 November 2023 14:46

RMC-035 reduces long-term adverse kidney events following cardiac surgery

Trial

Phase 2, AKITA

Conference

ASN 2023

Type

News article

28 November 2023 14:44

Obinutuzumab attenuates kidney decline in lupus nephritis

Presented By

Dr Brad Rovin, Ohio State University, OH, USA

Trial

Phase 2, NOBILITY

Conference

ASN 2023

Type

News article

28 November 2023 14:41

Clinical benefits of sparsentan for patients with FSGS

Presented By

Prof. Michelle Rheault, University of Minnesota, MN, USA

Trial

Phase 3, DUPLEX

Conference

ASN 2023

Type

News article

28 November 2023 14:41

Sparsentan outperforms irbesartan for treatment of IgAN

Presented By

Prof. Brad Rovin, Ohio State University, OH, USA

Trial

Phase 3, PROTECT

Conference

ASN 2023

Type

News article

28 November 2023 14:33

Small molecule PGE1 shows promise for nephronophthisis treatment in vitro and in vivo

Presented By

Prof. Sophie Saunier, Inserm, France

Conference

ASN 2023

Type

News article

28 November 2023 14:18

Isuzinaxib effective in patients with CKD and T2D

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:56

VALOR-CKD trial did not show any benefits for veverimer

Presented By

Dr Navdeep Tangri, Seven Oaks General Hospital, Winnipeg, Canada

Trial

Phase 3, VALOR-CKD

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:54

EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death

Presented By

Dr William Herrington, University of Oxford, UK

Trial

Phase 3, EMPA-KIDNEY

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:53

Combining UACR and GFR improves prediction of drug effect in CKD phase 2 trials

Presented By

Dr Tom Greene, University of Utah, USA

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:49

Dapagliflozin reduces number of hospitalisations in patients with CKD

Presented By

Dr Meir Schechter, Universitair Medisch Centrum Groningen, Netherlands

Trial

Phase 3, DAPA-CKD

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:47

Novel MSC therapy appears safe and effective in preventing decline in eGFR

Presented By

Dr Matthew Griffin, University of Galway, Ireland

Trial

Phase 1/2, NEPHSTROM

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:43

Dapagliflozin improves anaemia in patients with CKD with or without T2D

Presented By

Prof. Hiddo Heerspink, University of Groningen, Netherlands

Trial

Phase 3, DAPA-CKD

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:39

Balanced crystalloid solution better for deceased donor kidney transplantations

Presented By

Dr Michel G. Collins, Royal Adelaide Hospital, Australia

Trial

BEST-Fluids

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:36

Modified donor blood cells seem a promising option in kidney transplant recipients

Presented By

Dr Matthias Schaier, Heidelberg University, Germany

Trial

Phase 1

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:34

Wearable serum potassium-monitoring device serves haemodialysis patients well

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:22

Cooler dialysate does not offer any clinical benefits

Presented By

Prof. Amit Garg, London Health Sciences Centre and Western University, Ontario, Canada

Trial

MyTEMP

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:20

Sodium zirconium cyclosilicate maintains pre-dialysis serum potassium

Trial

Phase 3, DIALIZE China

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:18

Antiviral effect of MAU868 against BK virus prompts further research

Presented By

Dr Stanley Jordan, Cedars-Sinai Medical Center/Comprehensive Transplant Center, CA, USA

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:16

Medication-targeted alerts for the risk of AKI

Presented By

Dr F. Perry Wilson, Yale School of Medicine, CT, USA

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:13

Coaching with a DASH diet improves albuminuria

Presented By

Prof. Diedre C. Crews, Johns Hopkins University School of Medicine Equity, MD, USA

Trial

Five, Plus Nuts and Beans for Kidneys

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:09

Cemdisiran shows promise in IgA nephropathy

Presented By

Prof. Jonathan Barratt, University of Leicester, UK

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:58

Long-term nephroprotective effects of sparsentan in FSGS

Presented By

Dr Tarak Srivastava, Children’s Mercy Hospital, USA

Trial

Phase 2, DUET

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:55

Encaleret normalises mineral homeostasis in patients with ADH1

Presented By

Dr Kelly Roszko, National Institutes of Health, USA

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:52

Adding voclosporin to MMF and steroids results in long-term higher CRR in severe lupus nephritis

Presented By

Dr Hanni Menn-Josephy, Boston University School of Medicine, USA

Trial

AURORA 1, AURORA 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:49

Letter from the Editor

Editor

Dr Rachel Giles, Medicom Medical Publishers, the Netherlands

Conference

ASN 2022

8 December 2022 14:45

Selonsertib poses risk of AKI in patients with DKD

Presented By

Prof. Vlado Perkovic, University of New South Wales, Australia

Trial

Phase 2, MOSAIC

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:34

Significantly higher risk of overcorrection in hyponatraemic patients with standard bolus infusion

Presented By

Dr Anissa Pelouto, Erasmus Medical Center, Rotterdam, the Netherlands

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:29

Lowering blood pressure intervention favourable for CV outcomes

Presented By

Dr Amara Sarwal, University of Utah Health, UT, USA

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:27